AbbVie CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2012-04-10
- Employees
- 50K
- Market Cap
- -
- Website
- www.abbvieinvestor.com
- Introduction
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
40
Drug Approvals
Risankizumab Injection
- Product Name
- 利生奇珠单抗注射液
- Approval Number
- 国药准字SJ20250009
- Approval Date
- Mar 4, 2025
Risankizumab Injection (Subcutaneous Injection)
- Product Name
- 喜开悦
- Approval Number
- 国药准字SJ20250008
- Approval Date
- Mar 4, 2025
Brimonidine Tartrate Eye Drops
- Product Name
- 酒石酸溴莫尼定滴眼液
- Approval Number
- 国药准字HJ20160426
- Approval Date
- Oct 29, 2024
Brimonidine Tartrate Eye Drops
- Product Name
- 酒石酸溴莫尼定滴眼液
- Approval Number
- 国药准字HJ20160425
- Approval Date
- Oct 29, 2024
Brimonidine Tartrate Eye Drops
- Product Name
- 酒石酸溴莫尼定滴眼液
- Approval Number
- H20160426
- Approval Date
- Dec 27, 2019
Brimonidine Tartrate Eye Drops
- Product Name
- 酒石酸溴莫尼定滴眼液
- Approval Number
- H20160425
- Approval Date
- Dec 27, 2019
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
News
Global CLL Trial Landscape Shows Robust Activity, Highlights Regional Disparities
• A new report reveals that over 1,000 CLL clinical trials have been initiated globally since 2019, with North America leading at 37%, followed by Asia-Pacific at 34%. • CLL drug development includes 24 drugs in preclinical stages, 33 in Phase I, 30 in Phase II, and 4 in Phase III, with Bruton Tyrosine Kinase inhibitors dominating Phase III trials. • China led venture capital funding for CLL research from 2019 to 2023 with $1,813 million, closely followed by the United States with $1,805.6 million. • Targeted therapies, immunotherapy (CAR T-cell therapy), and precision medicine advancements have improved CLL treatment outcomes, with companies like AbbVie and BeiGene actively developing new therapies.